Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Damaged gastrointestinal mucosal proteins refer to the collection of proteins, such as albumin and fibrinogen, that become exposed at the site of erosions or ulcers in the gastrointestinal tract. These proteins serve as a therapeutic target for cytoprotective agents like sucralfate, which is a sucrose sulfate-aluminum complex. In the acidic environment of the stomach, sucralfate undergoes cross-linking to form a viscous, sticky paste that selectively binds to the positively charged proteins in the ulcer base. This interaction creates a physical barrier that shields the underlying tissue from the corrosive effects of gastric acid, pepsin, and bile salts, thereby facilitating the natural healing process of the mucosa. While not a single receptor or enzyme, these exposed proteins are critical for the localized action of specific gastroprotective medications.
Formation of a physical barrier through ionic binding to positively charged proteins (such as albumin and fibrinogen) exposed at the site of mucosal damage, protecting the area from further degradation by gastric acid, pepsin, and bile salts.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Damaged gastrointestinal mucosal proteins.